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Oxidative stress is involved in acute kidney injury due to
ischemia–reperfusion and chemotherapy-induced
nephrotoxicity. To investigate their basic mechanisms we
studied the role of nuclear factor-erythroid 2-p45-related
factor 2 (Nrf2), a redox-sensitive transcription factor that
regulates expression of several antioxidant and
cytoprotective genes. We compared the responses of
Nrf2-knockout mice and their wild-type littermates in
established mouse models of ischemia–reperfusion injury and
cisplatin-induced nephrotoxicity. Several Nrf2-regulated
genes encoding antioxidant enzymes/proteins were
significantly upregulated in the kidneys of wild type but not
Nrf2-knockout mice following renal ischemia. Renal function,
histology, vascular permeability, and survival were each
significantly worse in the Nrf2 knockout mice. Further,
proinflammatory cytokine and chemokine expression tended
to increase after ischemia in the knockout compared to the
wild-type mice. Treatment of the knockout mice with the
antioxidants N-acetyl-cysteine or glutathione improved renal
function. The knockout mice were more susceptible to
cisplatin-induced nephrotoxicity, and this was blunted by
N-acetyl-cysteine pretreatment. Our study demonstrates
that Nrf2-deficiency enhances susceptibility to both ischemic
and nephrotoxic acute kidney injury, and identifies this
transcription factor as a potential therapeutic target in
these injuries.
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Ischemia–reperfusion injury (IRI) is a common cause of
acute kidney injury (AKI) in both native and allograft
kidneys. Ischemic AKI in native kidneys is associated with a
high mortality rate of up to 50%.1–3 Ischemic injury to renal
allograft increases length of hospitalization and leads to
increased short- and long-term allograft loss. Another
common cause of AKI is nephrotoxicity, which limits the
use of many effective therapeutic agents, including the
chemotherapeutic agent cisplatin.4 Elucidating the patho-
genic mechanisms underlying AKI is critical to develop new
diagnostic tools and therapeutic strategies.
Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is a
basic leucine zipper redox-sensitive transcription factor that
regulates the expression of several cellular antioxidant and
cytoprotective genes. Nrf2-mediated transcriptional responses
have been shown to be protective in various experimental
diseases including LPS-induced sepsis (shock),5,6 oxidative lung
injury and fibrosis, asthma, smoking-induced emphysema,7–11
and brain IRI.12,13 A recent study14 has demonstrated elevated
levels of Nrf2 and its downstream target genes in the kidney
tissue of wild-type mice following induction of renal ischemia
and reperfusion. However, the functional role of Nrf2 in AKI
remains unclear. Because emerging evidence suggests that Nrf2
protects the lung and brain from acute injury through the
regulation of antioxidant gene expression,8 and oxidative stress
is known to occur in AKI,15 we hypothesized that Nrf2
deficiency would increase susceptibility to both ischemic and
nephrotoxic AKI. We first performed gene expression profiling
in the kidney of wild-type (Nrf2þ /þ ) and Nrf2-knock out
(Nrf2/) mice subjected to renal IRI. We found that several
antioxidant pathways were deregulated during ischemic AKI in
Nrf2/ mice. Nrf2/ mice had more pronounced changes
in renal function, histology, proinflammatory protein expres-
sion as well as microvascular permeability than those seen in
Nrf2þ /þ mice with ischemic AKI. We reconstituted the
antioxidant activity in the Nrf2/mice with N-acetyl cysteine
(NAC) or glutathione (GSH) to partially mitigate the effects of
Nrf2 deficiency. Using a cisplatin-induced AKI model, we
found that Nrf2-deficiency also lowered the threshold for
nephrotoxic injury and this was influenced by NAC.
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RESULTS
Upregulation of Nrf2 target genes in the kidneys of mice
subjected to ischemia–reperfusion
Using Affymetrix chips, our team previously demonstrated
upregulation of Nrf2 target genes in the kidney of NIH-Swiss
wild-type mice after moderate ischemia (30 min).14 In current
study, we explored whether Nrf2-regulated genes were altered
in a different strain of mouse [Nrf2þ /þ with CD1
background and the same mice with the Nrf2 gene deleted
(Nrf2/)] after 60 min renal ischemia and used a less
expensive array gene chip platform (Illumina, San Diego, CA,
USA). At 24 h after renal IRI, four of 15 tested Nrf2 target genes
were significantly upregulated in the kidney of Nrf2þ /þ
mice, but not in those of Nrf2/ mice. All upregulated genes
in the ischemic kidneys had a mean fold of change (FOC) of
1.5 or greater than those in the sham-operated kidneys and
with a q-value less than 5%. These genes were aldehyde
dehydrogenase (Aldh1a1, FOC: 1.91), growth arrest/DNA
damage-inducible 45 (GADD45, FOC: 2.37), and glutathione
S-transferase (Gsta2, FOC: 3.36; Gstp1, FOC: 1.89). (Figure 1).
Nrf2/ mice had worse renal function than Nrf2þ /þ mice
after ischemia
We then evaluated the direct role of Nrf2-deficiency on renal
function following renal IRI. Nrf2/ and Nrf2þ /þ mice
underwent 30 min bilateral renal ischemia followed by
reperfusion for up to 72 h. Serum creatinine (SCr) concen-
tration was measured as a marker of renal function at 0
(baseline), 24, 48, and 72 h after ischemia. All animals
survived to 24 h but four of six Nrf2/ mice and two of five
Nrf2þ /þ mice died by 72 h post ischemia. After ischemic
injury, Nrf2/ mice had significantly increased SCr at 24 h
(SCr in mg/dl, Nrf2/ vs Nrf2þ /þ : 2.67±0.21 vs
1.50±0.29, Po0.03) and a trend towards an increase at 48
and 72 h when compared with wild-type mice (Figure 2a).
Nrf2/mice had increased renal vascular permeability after
ischemia
We examined the effect of Nrf2 on renal microvascular injury
by using extravasation of albumin-bound Evans blue dye as a
marker of renal vascular permeability. Mice were subjected to
either 30 min of renal ischemia followed by 24 h reperfusion
or sham surgery. We found that after IRI, both Nrf2þ /þ
mice and Nrf2/ mice had significantly greater renal Evans
blue dye extravasations compared with the sham mice.
However, the Evans blue dye extravasations after IRI was
elevated in the kidneys of Nrf2/ mice compared with
Nrf2þ /þ mice. (Evans blue dye extravasations in mg/g:
797±71 vs 605±36. Po0.03, Figure 2b).
Nrf2/ mice had increased renal tubular injury after
ischemia
Kidneys from both Nrf2/ and Nrf2þ /þ mice were
harvested at 72 h post ischemia and processed for histological
examination with hematoxylin and eosin stain. A renal
pathologist (MH), blinded to the experimental groups,
scored tubular injury semiquantitatively, by focusing on
epithelial necrosis and infiltration of polymorphonuclear
leukocytes (PMN). Nrf2/ mice had greater tubular injury
(Score: 3.71±0.18 vs 3.14±0.14, Po0.03; n¼ 7) and PMN
infiltration (score: 2.57±0.30 vs 2.01±0.29, Po0.03; n¼ 7)
when compared with Nrf2þ /þ mice (Figures 2c and 3).
Nrf2/ mice had increased mortality rate after severe renal
ischemia
Thirty-minute bilateral renal ischemia is a moderate injury
model that has a relatively low mortality rate. To evaluate
whether Nrf2 deficiency worsens AKI-induced mortality, we
subjected Nrf2/ mice and Nrf2þ /þ mice to 60 min
bilateral renal ischemia (severe ischemia model) and analyzed
mortality rates over the next 72 h. All 17 Nrf2/ mice died
by 72 h post ischemia whereas only two of eight (2/8)
Nrf2þ /þ mice died by 72 h, demonstrating a survival
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Figure 1 | Up/downregulated Nrf2 antioxidant genes in the
ischemic kidney. Nrf2þ /þ (wild type) and Nrf2/ (deficient)
mice underwent renal ischemia followed by reperfusion for 24 h.
Total RNA was isolated from the collected kidneys and processed
for gene microarray. The data is expressed as a fold change of
each gene in ischemic kidney from wild-type mice over that from
Nrf2/ mice (a) or each gene in ischemic kidney over that in
sham-operated kidney (b). (*Po0.05 vs Nrf2/). Gene symbols:
Aldh1a1 (7), aldehyde dehydrogenase family 1, subfamily A1 (7);
Gadd45, growth arrest/DNA-damage-inducible 45; Gclc (m),
glutamate-cysteine ligase, catalytic (modified) subunit; Gpx2(3),
glutathione peroxidase 2 (3); Gsr, glutathione reductase 1; Gsta2,
glutathione S-transferase, a-2; Gstm4(5), glutathione S-transferase,
mu 4 (5); Gstp1, glutathione S-transferase, pi 1; Hmox1, heme
oxygenase (decycling) 1; Nqo1, NAD(P)H dehydrogenase, quinone
1; Txnrd1, thioredoxin reductase 1.
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disadvantage in the Nrf2/ mice compared with Nrf2þ /þ
mice (P¼ 0.008 by log-rank test; Figure 2d). In contrast, in
mice that underwent 30 min renal ischemia, four out of six
Nrf2/ mice and two out of five Nrf2þ /þ mice died by
72 h – the survival rate between these two genotypes was not
significantly different (mean survival time: Nrf2/, 54 h vs
Nrf2þ /þ , 67 h, P¼ 0.15; Figure 2d).
Proinflammatory mediators in ischemic kidney
To examine potential inflammatory mechanisms by which
ischemic AKI was accentuated in Nrf2/ mice, we measured
proinflammatory mediator cytokine protein using Bio-Plex
cytokine/chemokine assay techniques (similar to multiple
ELISA combined) in the kidneys from both Nrf2þ /þ mice
and Nrf2/ mice subjected to IRI or sham-surgery. The
expression level of each cytokine/chemokine is presented as
fold of change (FOC) of each protein in ischemic kidneys over
the level of the same cytokine/chemokine in sham kidneys. At
72 h after ischemia, Nrf2/ mice had a trend towards
increase in measured cytokines and chemokines in ischemic
kidney when compared with Nrf2þ /þ mice. These proteins
are IL-2 (Mean±s.d.: 7.15±1.88 vs 5.18±1.78, P¼ 0.26), IL-6
(Median: 2.33 vs 2.13, P¼ 0.82), KC (Median: 14.1 vs 5.9,
P¼ 0.05) and G-CSF (Mean±s.d.: 11.66±8.33 vs 5.31±2.79,
P¼ 0.06) and a trend towards a decrease in RANTES (Median:
2.45 vs 4.53, P¼ 0.29, Figure 4).
Supplementation with antioxidants NAC or GSH improved
AKI in Nrf2/ mice
To test whether Nrf2 protects mice from renal IRI through an
antioxidant pathway(s), we pretreated Nrf2/ mice and
Nrf2þ /þ mice with antioxidant NAC or GSH prior to
ischemia. Control mice were treated with saline. All mice
underwent 30 min bilateral renal ischemia and all mice were
alive at 24 h after ischemia. Nrf2/ mice treated with GSH
or NAC had significantly smaller increases in serum
creatinine level at 24 h than those pretreated with saline
(SCr saline vs GSH vs NAC: 3.13±0.13 vs 1.02±0.45 vs
1.40±0.37, Po0.001 by one-way ANOVA, n¼ 6 in NAC or
GSH and 13 in saline) (Figure 5a). In contrast, pretreatment
of wild-type Nrf2þ /þ mice with GSH or NAC did not
improve renal function at 24 h after ischemia. (SCr:
2.71±0.19 vs 2.52±0.62 vs 2.53±0.18, P¼ 0.87, n¼ 4–11)
(Figure 5b). Histological analysis showed that pretreatment
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Figure 2 | Comparison of renal function, kidney histology,
kidney vascular permeability, and survival in Nrf2þ /þ and
Nrf2/ mice after renal ischemia. All mice underwent 30 (a–d)
or 60 (d) min bilateral renal ischemia followed by reperfusion for
up to 72 h. Serum creatinine (SCr), Evans blue dye extravasations
(EBDE), tubular injury score and mouse survival was analyzed. (a:
SCr. *Po0.02 vs Nrf2þ /þ , n¼ 6; b: EBDE. *Po0.03 vs Nrf2þ /þ ,
n¼ 6–8; c: tubular injury score. *Po0.03 vs Nrf2þ /þ , n¼ 7; d:
survival. *P¼ 0.008 vs Nrf2þ /þ 60 min by log-rank test. n¼ 7–17
in 60 min ischemia; n¼ 5–6 in 30 min).
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Figure 3 | Photomicrographs of kidney histology from
Nrf2þ /þ mice and Nrf2/ mice. All mice underwent either
30 min bilateral renal ischemia or sham operation and were killed
72 h later. The collected kidneys were stained with H&E for
histological examination. Nrf2/ mice had more tubular injury
than Nrf2þ /þ mice after ischemia. (a and e: sham kidney from
Nrf2þ /þ mice; b and f: sham kidney from Nrf2/ mice;
c and g: ischemic kidney from Nrf2þ /þ mice; d and h: ischemic
kidney from Nrf2/ mice. Asterisks indicate dilated tubules or
cast formation. Arrows, necrotized tubules).
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with NAC, but not GSH, improved epithelial necrosis
(Median score: 3.5 vs 3.0, P¼ 0.011 by Rank Sum test) and
PMN infiltration (Median score: 4.0 vs 2.0, P¼ 0.003,
n¼ 6–12) in Nrf2/ mice after ischemia (Figure 5c). In
Nrf2þ /þ mice, pretreatment with GSH improved tubule
necrosis after ischemia (Mean±s.e.m.: saline vs GSH vs
NAC, 3.4±0.13 vs 2.75±0.25 vs 3.67±0.17, P¼ 0.021 by
one-way ANOVA, n¼ 3–10, Figure 5d).
Supplementation of NAC reduced proinflammatory
mediators in ischemic kidney
We determined if the antioxidant pretreatment that improved
renal function after IRI in Nrf2/ mice could also decrease
the generation of proinflammatory mediators in the ischemic
kidney. We measured the protein levels of proinflammatory
mediators by Bio-plex protein array in the ischemic kidneys
from NAC pretreated Nrf2/ mice and Nrf2þ /þ mice at
24 h after ischemia. We found that in both Nrf2/ and
Nrf2þ /þ mice, pretreatment with NAC mitigated the rise
in IL-6 that occurred in mice pretreated with saline. (IL-6,
median, saline vs NAC: Nrf2/, 12.7 vs 1.91, P¼ 0.004;
Nrf2þ /þ , 50.2 vs 2.2, P¼ 0.04; Figure 6).
Worse renal function and survival after cisplatin in Nrf2/
mice compared with Nrf2þ /þ mice
We tested the effect of Nrf2 deficiency in mice in another
clinical form of AKI, cisplatin-induced nephrotoxicity. All
mice received a single intraperitoneal injection of cisplatin at
a dose of 20 mg/kg and were observed for 7 days. During the
follow-up, all four Nrf2/ mice died between days 3 and 7,
whereas only one of five Nrf2þ /þ mice died during this
period. The survival rate of Nrf2þ /þ mice was higher than
that of Nrf2/ mice (Po0.02 by log-rank test; Figure 7b).
The SCr in Nrf2/ mice was significantly increased on
day 3 to a level of 2.98±1.12 mg/dl, whereas that of the
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renal function and kidney tubular injury score (c and d) was
evaluated. a: SCr in Nrf2/ mice. *Po0.001 and **Po0.003 vs
saline, n¼ 6–13; c: *P¼ 0.011 and **P¼ 0.003 vs saline, n¼ 6–12;
d: *P¼ 0.021 vs saline, n¼ 3–10. Epi: epithelium; PMN:
polymorphonuclear leukocyte.
100
10
1
100
a
b
10
1
*
*
Nrf2–/– AKI+saline
Nrf2–/– AKI+NAC
Nrf2+/+ AKI+saline
Nrf2+/+ AKI+NAC
FO
C 
ov
er
 S
ha
m
(S
em
i-lo
g s
ca
le)
FO
C 
ov
er
 S
ha
m
(S
em
i-lo
g s
ca
le)
IL-
1b
IL-
1b
IL-
6
IL-
6
TN
F-a
TN
F-a
IFN
-g
IFN
-g
KC
KC
MI
P-1
a
MI
P-1
a
RA
NT
ES
RA
NT
ES
MC
P-1
MC
P-1
Figure 6 | Effect of NAC treatment on ischemic kidney
cytokines and chemokines. All mice were pretreated with either
NAC (500 mg/kg, i.p.) or saline 24 h before renal ischemia. The
total protein was extracted from the harvested kidneys and
processed for cytokine/chemokine protein array. a: Nrf2/ mice,
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Nrf2þ /þ mice was only 0.47±0.21 mg/dl (P¼ 0.049,
Figure 7a) at that time point.
Supplementation of antioxidant NAC reduced cisplatin
nephrotoxicity in Nrf2/ mice
To test if the enhanced susceptibility to cisplatin-induced
nephrotoxicity in Nrf2-deficient mice was due to antioxidant
mechanisms, we compared the effect of supplementation of
NAC on renal function in mice with higher dose of cisplatin
(30 mg/kg). We pretreated Nrf2/ mice and Nrf2þ /þ
mice with exogenous NAC (500 mg/kg, i.p.) 24 h before
cisplatin injection. We found that Nrf2/ mice with NAC,
but not Nrf2þ /þ mice, had a significantly less increase in
SCr at 24 h after cisplatin injection when compared with
saline pretreated mice. (SCr: Nrf2/, saline vs NAC,
4.16±0.14 vs 1.83±0.49, Po0.01. Figure 8).
DISCUSSION
In this study, we demonstrated that genetic deficiency in
Nrf2-mediated transcriptional responses, especially antiox-
idant pathways, enhances susceptibility to both ischemic and
nephrotoxic AKI in mice. Our findings have revealed that
after IRI, Nrf2-deficiency leads to increased mortality
accompanied by augmented kidney dysfunction and vascular
permeability. However, supplementation of exogenous anti-
oxidants (NAC or GSH) to Nrf2/ mice significantly
improved renal function and histological injury, suggesting
that oxidative stress may play a role in IRI-related kidney
damage in the context of Nrf2-deficient redox signaling.
Nrf2 deficiency also contributed to increased mortality and
kidney dysfunction in a cisplatin-induced experimental
model of AKI.
Gene expression profiling revealed that several antioxidant
genes that are known to be regulated by Nrf2 were
upregulated in ischemic kidneys of wild-type (Nrf2þ /þ )
mice, but not of Nrf2/ mice. The upregulated genes
included aldehyde dehydrogenase (ALDH1A1 and ALDH1A7),
growth arrest and DNA damage (GADD45G), and gluta-
thione S-transferases (GSTA2 and GSTP1). These results are
consistent with those of a previous study that subjected a
different strain of mice (NIH-Swiss) to 30 min renal ischemia
and used the Affymetrix platform.14 However, we did not
find significant changes in the expression levels of the Nrf2-
target gene, NADPH quinone oxidoreductase, in our current
experimental conditions. Likewise, Leonard et al.14 did not
detect changes in the expression levels of GADD45G in their
experimental conditions. It is unclear whether this discre-
pancy is due to genetic differences in mouse strain (NIH-
Swiss vs CD-1 mice) or variations in experimental condi-
tions, such as the different microarray platforms (Affymatrix
vs Illumina) used in these two studies. Investigation that is
more detailed is necessary to address this discrepancy.
Given that Nrf2-regulated genes were found to be
upregulated in the post-ischemic kidney, we examined the
role of Nrf2 by comparing renal IRI in Nrf2/ mice and
wild-type Nrf2þ /þ mice. We found that compared with
wild-type mice, Nrf2/ mice had significantly greater
renal dysfunction as evidenced by a greater rise in serum
creatinine at 24 h after ischemia, and greater histological
injury with a higher tubular injury score, and increased
renal vascular permeability following IRI. Thus, it appears
that lower expression of Nrf2-related antioxidant genes
contributes to increased kidney damage in Nrf2/ mice
during IRI. In support of this conclusion, a recent study
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revealed that depressed expression of the Nrf2 gene might
contribute to increased IRI in older donor liver after liver
transplantation.16
To address whether Nrf2-regulated gene expression,
especially the antioxidant response, confers protection
against AKI from IRI, we supplemented Nrf2/ mice with
the antioxidants, NAC or GSH, prior to IRI. We found that
pretreatment with either NAC or GSH significantly improved
renal function (serum creatinine levels) after ischemia.
However, we would like to point out that, although
antioxidant supplementation significantly improved renal
function, NAC or GSH supplementation only had a modest
effect on kidney structural improvement in Nrf2-mice
subjected to IRI. It is likely that Nrf2-regulated gene
expression other than antioxidant responses may play a role
in the repair of kidney structural injury caused by IRI. In
support of this notion, we have shown by expression profiling
that Nrf2 regulates gene expression in both a GSH-dependent
and a GSH-independent manner in lung epithelial cells.17
Some of these include various growth factors and growth
factor receptors as well as structural genes. Thus, it is possible
that antioxidant gene expression could not completely restore
Nrf2-regulated gene expression in Nrf2/ mice. Alterna-
tively, it is possible that antioxidants can directly or indirectly
regulate creatinine levels in Nrf2/ mice, either at the level
of creatinine generation, clearance or both.
Antioxidant (NAC) supplementation has been shown to
be protective in number rodent models of experimental
kidney IRI.18–21 For example, de Araujo et al.22 have shown
that NAC supplementation confers protection against
ischemic AKI, when combined with magnesium supplemen-
tation. However, Pincemail et al.23 have shown that NAC
dose not improve renal tubular injury in a rabbit model of
IRI. We found that antioxidant supplementation had no
significant effect on improving renal function in wild-type
mice. Although we cannot rule out the possibility that
Nrf2þ /þ mice might be protected if treated at a different
dose and or for a longer time, the protective effects of
NAC on ischemia- and cisplatin-induced AKI in Nrf2-
deficient mice, but not in wild-type mice suggests that both
oxidative stress-dependent and independent mechanisms
contribute to AKI. Alternatively, it is possible that antiox-
idant supplementation is only beneficial to the Nrf2/
mice in the setting of a defective antioxidant response. It
should be noted that antioxidant supplementation have
yielded contradictory or inconclusive observations in several
experimental models of AKI. In patients who underwent
aortic/cardiac surgery or orthotropic heart transplantation,
NAC treatment showed little renal protection.24–26 Given the
fact that Nrf2 is crucial for the induction of various networks
of gene expression, including the antioxidant enzymes27,28
and that NAC or GSH supplementation incompletely
improves renal function in Nrf2/ mice, it is very likely
that Nrf2 regulates renal function and injury through other
alternative pathways, in addition to GSH biosynthesis. For
example, it has been shown that heme oxygenase, a
transcriptional target of Nrf2, confers renal protection
against ischemia-induced AKI.29,30
To further elucidate mechanisms by which Nrf2-deficiency
enhances susceptibility to renal IRI, we examined several
proinflammatory cytokine proteins in the kidneys from
Nrf2þ /þ mice and Nrf2/mice. We found trends toward
higher levels of IL-6, KC, and G-CSF in Nrf2/ mice
compared with wild-type mice at 72 h after ischemia. KC is a
putative biomarker as well as a mediator of AKI.31 Therefore,
an increase in the levels of KC is consistent with the
functional and structural enhancement of damage in Nrf2-
deficient mice. In contrast, Nrf2/ mice displayed different
levels of IL-1, IL-2, and IL-6 and diminished level of RANTES
and MCP-1 at late time point as compared with wild-type
mice. To determine whether the improvement in renal
function afforded by exogenous antioxidant supplementation
during ischemia–reperfusion was associated with attenuation
of specific proinflammatory mediators in the kidney, we
measured the levels of proinflammatory mediators in the
ischemic kidneys from Nrf2/ mice, and also Nrf2þ /þ
mice at 24 h after ischemia. We found that pretreatment with
antioxidant reduced the increase in IL-6 levels both in
Nrf2/ mice and Nrf2þ /þ mice when compared with
vehicle-treated group, suggesting that Nrf2-dependent anti-
oxidant response could lessen generation of proinflamma-
tory mediators induced by ROS during IRI. Whether Nrf2
directly or indirectly modulates the expression levels of these
cytokine/chemokines is unclear and warrants further study.
Nephrotoxicity is another leading cause of AKI.4 To
examine whether Nrf2 is also protective in nephrotoxic
injury, we examined the effect of Nrf2 deficiency in a
cisplatin-induced nephrotoxicity model. We found that
Nrf2/ mice had severe renal dysfunction and higher
mortality than did Nrf2þ /þ mice following administration
of cisplatin. Similar to ischemic AKI, supplementation of
NAC significantly improved renal function in cisplatin-
treated Nrf2/ mice. This finding has important implica-
tions for minimizing cisplatin toxicity by supplementation of
exogenous antioxidant in patients who are deficient in
endogenous antioxidant.
In summary, our data demonstrates that Nrf2 plays a
protective role in experimental AKI, and that this protection
is mediated, in part, through an endogenous antioxidant
pathway. Modulating the Nrf2-regulated pathways may be an
attractive target for future therapeutic studies in AKI,
particularly in the setting of antioxidant deficient or other
susceptible populations.
METHODS
Mice
CD-1 background Nrf2-deficient mice (Nrf2–/–) were generated as
described earlier27 and the wild-type mice (Nrf2þ /þ ) with same
background were used as controls. Breeding pairs of ICR/Sv129-
Nrf2þ / mice were obtained from a colony at Tsukuba University
(Tsukuba, Ibaraki, Japan) and maintained in the Johns Hopkins
animal facility with air-conditioning and 12–10 h light–dark cycle
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under a pathogen-free condition. All experimental protocols
conducted in these mice were approved by the Johns Hopkins
University Animal Care and Use Committee and were performed in
accordance with NIH guidelines. All animals had free access to food
and water during the experiments.
Renal ischemia–reperfusion injury model
An established model of renal IRI was used.32 Animals were
anesthetized with intraperitoneal injection of sodium pentobarbital
at 75 mg/kg. Abdominal incisions were made and the renal pedicles
were bluntly dissected. A microvascular clamp was placed on each
renal pedicle for 30 or 60 min. During the procedure, animals were
well hydrated with warm saline, (1 ml at the beginning of ischemia
and 1 ml at the beginning of reperfusion) and mice body
temperatures were maintained constantly at 35.5–371C on a heating
pad (401C) until awake. After removing the clips, the wounds were
sutured and the animals were allowed to recover.
Administration of cisplatin
Cisplatin (cis-diammineplatinum II dichloride, Sigma-Aldrich, St
Louis, MO, USA) was dissolved in 0.9% saline at a concentration of
2 mg/ml. Mice were given a single i.p. injection either at a low dose
of 20 mg/kg or at a higher dose of 30 mg/kg body weight. This high
dose was chosen based on our preliminary studies that showed a
lower dose did always give consistent and significant renal
dysfunction. A dose at 30 mg/kg produced a predictable combina-
tion of survivability and acute renal failure as early as at 24 h and
reached a peak at 72 h after cisplatin administration in C57BL6 wild-
type mice in our previous report.33
Assessment of renal function
Blood samples were obtained from mice through tail vein prior to
(0) and at 24, 48, and 72 h or day 4 and 7 after ischemia or cisplatin.
Serum creatinine concentration was measured as a marker of renal
function by a Roche Cobas Fara automated system (Roche, Nutley,
New Jersey, USA) using a Creatinine 557 kit (Sigma Diagnostics, St
Louis, Missouri, USA).
Evaluation of kidney histology
Formalin-fixed and paraffin-embedded kidney tissues were cut and
stained with hematoxylin and eosin. Only the right kidney from each
mouse was examined and scored. Renal tubular injury was assessed
using a semi-quantitative scale. A renal pathologist (MH) who was
blinded to the experimental groups scored the magnitude of tubular
epithelial cell necrosis and interstitial PMN infiltration into five levels
based on the estimation of the fraction of tubules with epithelial
necrosis in the outer medulla and region of the cortico–medullary
junction in a high power field under light microscope. We scored
tubular injury according to the following schema (0: none; 0.5:o10%;
1: 10–25%; 2: 25–50%; 3: 50–75%; 4: 475%).34 We also counted the
number of neutrophils per high power ( 400) field in 10 consecutive
high power fields in the region of the cortico–medullary junction,
starting with the field containing the greatest number of neutrophils. A
neutrophil infiltration score was then determined according to the
following scale34: 0, 0–1; 1, 2–10; 2, 11–20; 3, 21–40; 4, 440 or too
many to count.
Renal vascular permeability
Renal microvascular injury secondary to ischemia was assessed by
extravasation of albumin-bound Evans blue dye from the kidney
parenchyma.35 Thirty minutes before the mice were killed, Evans
blue dye (Sigma Chemical Co., St Louis, MO, USA) (2 ml/kg 1% dye
in 0.9% of saline) was injected through the right jugular vein
whereas the animals received light ether anesthesia. Immediately
after the animals were killed (by an overdose of pentobarbital), the
circulation was cleared by transcardiac perfusion using 10 ml of
heparinized saline (0.5 ml of heparin in 500 ml of 0.9% NaCl). The
flushed kidneys were removed and dried at 601C for 3 days. The
dried kidneys were weighed and homogenized in formamide with a
ratio of 1–20 (w/v). The homogenates were incubated at 601C for
18 h (overnight), and then centrifuged for 30 min at 14,000 r.p.m. at
41C to remove suspended particulate matter. The quantity of
extracted EB in the supernatant was determined by measuring
absorbance at a dual-wavelength of 620/635 nm and corrected for
the extraction volume. A standard curve of Evans blue in a blank
formamide was used to convert absorbency into micrograms of
Evans blue per gram of dried tissue.
Gene microarray in the kidney
Total RNA was extracted from kidney tissues using the Trizol Reagent
(Invitrogen, Carlsbad, CA, USA 92008, cat. no. 15596-026). Additional
purification was performed on RNAeasy columns (Qiagen, Valencia,
CA, USA 913555, cat. no. 74104). The quality of total RNA samples
was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA, USA). RNA samples were labeled according to Illumina
recommended protocols. In brief, 0.5mg of total RNA from each
sample was labeled by using the Illumina Total Prep RNA
Amplification Kit (Ambion, Austin, TX, USA 78744-1832, cat. no.
IL1791) in a process of cDNA synthesis and in vitro transcription
similar to that of other chip manufacturers used. Single-stranded RNA
(cRNA) was generated and labeled by incorporating biotin-16-UTP
(Roche Diagnosics GmbH, Mannheim, Germany, cat. no.
11388908910). 0.85mg of biotin-labeled cRNA was hybridized (16 h)
to Illumina’s Sentrix MouseRef-8 Expression BeadChips (Illumina
92121-1975). The hybridized biotinylated cRNA was detected with
streptavidin-Cy3 and quantitated using Illumina’s BeadStation 500GX
Genetic Analysis Systems scanner.
Analysis of array data
Preliminary analysis of the scanned data was performed using
Illumina BeadStudio software. The basic Illumina data is returned
from the scanner in the form of an ‘.idat’ file, which contains single
intensity data values/gene following the computation of a trimmed
mean average for each probe type represented by a variable number
of bead probes/gene on the array. The Bead Studio software returns
information on the number and s.d. of all the bead measurements
per probe/gene. A detection call based on a comparison between the
measured intensity for a single probe/gene, and the intensities
measured for a large number of negative control beads built-in to the
BeadChip arrays is also given. (D¼%above negative/100,
1¼ perfect, that is, the intensity value of a gene is greater than all
the intensities for every negative control tested) Background filtering,
defined as any gene below D¼ 0.95 for 75% of samples, was
eliminated from further analysis. Then the data was log transformed
and normalized to chipwise mean using CLUSTER tool36 and
processed using Significance Analysis of Microarray (SAM) software.
Fold changes and false discovery rate were computed by Significance
Analysis of Micro arrays (SAM) method37 using 1000 permutations
and 1.5-fold change as cutoff values. Gene with false discovery rate
(Qo5%) were considered significantly affected by IRI and
dynamically link to Gene Ontology (GO) terms using tabulated
data Mouse430A_2 Annotations, CSV (8.6 MB, 4/14/06) obtained
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from NetAffx provided databases (http://www.affymetrix.com/support/
technical/byproduct.affx?product=moe430A-20). As the mouse GO is
not yet complete, we enriched mouse GO with orthologous human
GO terms using Mouse430A_2 Annotations, Orthologs (4.6 MB,
4/14/06). The mouse/human GO database was then linked to
IRI-related candidate genes and searched for endothelium and cell
adhesion terms.
Cytokines/chemokines protein array
To examine proinflammatory molecules generated by ischemia–
reperfusion injury, protein levels of IL-1a/b, IL-2, IL-3, IL-4, IL-6, IL-
10, IL-12, IFN-g, TNF-a, KC, G-CSF, MIP-1a, RANTES, and MCP-1
were measured in mice kidneys by Bio-Plex multiple cytokine array
(Bio-Rad Laboratories Inc., Hercules, CA, USA) earlier described in
depth.38 Briefly, a portion of snap frozen tissue was homogenized in
a cell-lysis buffer, and the homogenates were centrifuged at
12,000 r.p.m. for 15 min at 41C. Total protein concentration in each
supernatant was determined using a Bio-Rad Protein Assay Kit, and
the measured protein level in each sample was adjusted to 500mg/ml
with cell lysis buffer. Each sample was first incubated with a mixture
of all types of micro-beads for 90 min at room temperature followed
by incubation with biotinylated detection antibodies for 30 min,
then with a streptavidin-coupled phycoerythrin for 10 min room
temperature. Finally, the samples were subjected to a flow
cytometric system. All acquired data was analyzed using Bio-Plex
Manager 3.0 software (Bio-Rad).
Administration of N-acetyl-cysteine or gluthathione
To examine the effect of replenishing antioxidant in Nrf2 deficiency
on renal IRI, a group of Nrf2/mice was pretreated either with N-
acetyl cysteine (NAC, Sigma-Aldrich) at 500 mg/kg body weight
(i.p.) 24 h and 1 h before ischemia. The dose and timing of NAC
administration were based on and modified from the study which
showed NAC improved survivals in both of Nrf2/ mice and
wild-type mice from lethal dose of LPS.5 Another group of mice
were pretreated with glutathione-reduced ethyl ester (GSH, Sigma-
Aldrich) at 5 mM/kg (i.p.) per day for 3 days before ischemia. This
dose and timing was chosen based on our previous studies.39,40
Statistics
Statistical analysis was performed with professional statistics soft-
ware SigmaStat (3.1) and all quantitative or semi-quantitative data
presented in this study were automatically checked for assumption
before performing any of the comparisons. Data passed both
Normality and Equal Variance tests are presented as mean±s.e.m.
and the data failed either of assumption tests are presented as
median with confidence. Single comparison between two groups was
performed with Mann–Whitney rank sum t-test whether assumption
tests failed or with an unpaired, two-tailed Student’s t-test whether
assumption tests passed. Multi-comparison among three or more
groups was performed by an ANOVA post hoc test. Cumulative
survival was analyzed by Kaplan–Meier log-rank test. Statistical
significance of difference was defined when the P-value o0.05.
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